NABP Compounding Pharmacy Accreditation — Frequently Asked Questions
Common questions from 503A compounding pharmacies and 503B outsourcing facilities about NABP Compounding Pharmacy Accreditation. For situation-specific guidance, schedule a free discovery session.
What is NABP Compounding Pharmacy Accreditation?
NABP Compounding Pharmacy Accreditation is a voluntary national accreditation for compounding pharmacies — both 503A and 503B — that demonstrates alignment with USP compounding standards, federal and state law compliance, and patient safety commitment. It provides a nationally recognized quality credential distinguishing compliant compounders from those operating outside established quality frameworks.
Does the accreditation cover both 503A and 503B compounders?
Yes. NABP Compounding Pharmacy Accreditation is available to both 503A patient-specific compounders and FDA-registered 503B outsourcing facilities. Standards are calibrated to the applicable regulatory framework — 503B facilities are evaluated against CGMP requirements and FDA's 503B-specific standards in addition to NABP's criteria.
What is the VPP inspection prerequisite?
Applicants must complete a prerequisite Verified Pharmacy Program (VPP) on-site inspection within 6 months of the application date. The VPP inspection evaluates the pharmacy's physical facility and operations against applicable standards. It is separate from the accreditation documentation review. IHS prepares clients for VPP inspections through a mock walkthrough that identifies gaps before the actual inspection.
Which USP chapters apply to compounding pharmacy accreditation?
USP Chapter 795 applies to non-sterile compounding; USP Chapter 797 applies to sterile compounding; USP Chapter 800 applies to hazardous drug compounding. NABP requires compliance with all applicable chapters based on the pharmacy's compounding activities. USP 797 was substantially revised with requirements fully effective in 2023, creating significant new compliance obligations for sterile compounders.
What bulk drug substance restrictions apply?
Under 503A, compounders can only use bulk substances in the USP/NF monograph or on FDA's 503A bulk list. Under 503B, bulk substances can only be used if the compound is on FDA's drug shortage list or the 503B bulk list. These lists evolve through FDA rulemaking. IHS advises clients on current bulk drug substance compliance as part of every engagement.
What are the personnel competency requirements for sterile compounding?
Under USP 797, personnel must demonstrate competency through media fill testing, gloved fingertip sampling, garbing competency assessments, and technique-specific evaluations. Competency must be re-evaluated at defined intervals and when new techniques or products are introduced. Personnel competency documentation is one of the most frequently cited deficiency areas in compounding accreditation reviews.
Does compounding pharmacy accreditation require environmental monitoring?
Yes — for sterile compounding pharmacies. USP 797 requires ongoing environmental monitoring of ISO-classified cleanrooms, including viable and non-viable particle monitoring, surface sampling, and air sampling at defined frequencies. Results must be documented, trended, and used to trigger corrective actions when action levels are exceeded.
Can a pharmacy with an FDA Warning Letter apply for accreditation?
An unresolved FDA Warning Letter is a significant eligibility risk for NABP Compounding Pharmacy Accreditation. Pharmacies with prior FDA enforcement history should discuss their specific situation with IHS before initiating an application.
Is NABP Compounding Pharmacy Accreditation required by law?
No — it is voluntary. However, some health systems, hospital networks, and physician groups require accreditation as a condition of purchasing compounded products. The primary value proposition is market differentiation and patient/prescriber confidence.
How does IHS help compounding pharmacies prepare for accreditation?
IHS provides regulatory framework assessment, USP compliance gap assessment, VPP inspection preparation via mock walkthrough, documentation development, and application preparation. Thomas G. Goddard, JD, PhD — IHS's principal consultant and former Chief Operating Officer and General Counsel of URAC — leads every engagement.
More Questions?
Schedule a Free Discovery Session with IHS to discuss your compounding pharmacy's specific accreditation questions.